Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

135.71 1.24 −0.91%
Market cap
$13.9B
P/E
19.2×
Fwd P/E
30.5×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
22.09% 22.50% 16.38% 14.96%

+8 more TTM periods

Piotroski F-Score
6 7 7 5
ROA
15.26% 15.56% 11.46% 10.97%
ROIC
15.04% 23.58% 21.83% 18.21%
Return on Tangible Assets
82.66% 39.44% 25.61% 26.46%
Average Days of Receivables
95.96 90.37 87.64 99.05
Free Cash Flow per Share
8.62 8.27 7.52 5.97
Free Cash Flow
870.40 831.30 748.70 593.10
Capital Expenditures
(27.70) (32.40) (34.00) (43.70)
Other line items
Cash ROIC
21.32% 17.60% 15.82% 14.40%
Accounts Receivable Turnover
4.55 4.83 4.91 4.44
Accounts Payable Turnover
0.11 0.09 0.09 0.09
Inventory Turnover
0.86 0.92 0.82 0.74
Average Days of Payables
4,238.93 4,976.10 4,723.98 4,982.93
Days of Inventory on Hand
546.45 415.21 483.40 590.99
Tax Rate
(0.25) (0.29) (0.32) (0.32)
Research and Development Expense of Revenue
33.52% 33.80% 35.51% 35.15%
Selling, General and Administrative Expense of Revenue
40.06% 38.62% 40.42% 42.58%
Share Based Compensation of Revenue
6.95% 7.17% 7.62% 8.41%
Interest Coverage
92.42 — — —
Operating CF/Net income
1.27 1.29 1.64 1.49
Depreciation/Fixed assets
0.42 0.19 0.19 0.04
Capex/Depreciation
(0.74) (1.89) (1.95) (12.49)
Revenue per Share
33.41 30.87 28.75 26.99
Operating CF per Share
8.89 8.59 7.87 6.41
Capex per Share
(0.27) (0.32) (0.34) (0.44)
Capex to Sales
0.01 0.01 0.01 0.02

Fold the line items

Columns are period end dates